Alpine Immune Sciences (ALPN) stock forecast for 2022. Forecast tables and graphs.

Alpine Immune Sciences (ALPN) stock forecast for 2022

Last update: February 3, 2023 (06:39)

Sector: Healthcare

The share price of Alpine Immune Sciences, Inc. (ALPN) now

What analysts predict: $14.4
52-week High/Low: $10.3 / $4.82

50/200 Day Moving Average: $7.11 / $7.74

This figure corresponds to the Average Price over the previous 50/200 days. For Alpine Immune Sciences stocks, the 50-day moving average is the resistance level today.

For Alpine Immune Sciences stocks, the 200-day moving average is the resistance level today.

Are you interested in Alpine Immune Sciences stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Alpine Immune Sciences stock price in 2022. How much will one Alpine Immune Sciences share be worth in 2022? Is it worth taking profit / loss on Alpine Immune Sciences stock now or waiting? What are analysts' forecasts for Alpine Immune Sciences stock?

We forecast Alpine Immune Sciences stock performance using neural networks based on historical data on Alpine Immune Sciences stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Alpine Immune Sciences stock prediction results are shown below and presented as a graph, table and text information.

Alpine Immune Sciences stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Alpine Immune Sciences analysts is $14.4.

Today 200 Day Moving Average is the support level (7.74 $).

50 Day Moving Average is the support level (7.11 $).

Historical and forecast chart of Alpine Immune Sciences stock

The chart below shows the historical price of Alpine Immune Sciences stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Alpine Immune Sciences stock price can be found in the table below.

Alpine Immune Sciences (ALPN) Forecast for 2022

Month Target Pes. Opt. Vol., %

Alpine Immune Sciences information and performance

Alpine Immune Sciences, Inc. Is a biopharmaceutical company. The company is focused on the discovery and development of protein immunotherapy for the treatment of cancer, autoimmune and inflammatory diseases. The Company’s scientific platform uses a directed evolutionary process to convert native immune system proteins from the immunoglobulin superfamily (IgSF) into multipurpose therapeutic drugs capable of modulating the human immune system. Its candidate products include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulant (ICOS) and differentiation cluster 28 (CD28) antagonist for the treatment of autoimmune and inflammatory diseases. His cancer program is ALPN-202, a conditional CD28 co-stimulator and dual checkpoint inhibitor for cancer treatment. ALPN-303 is a dual antagonist of B-cell cytokines for the treatment of B-cell mediated diseases.

Alpine Immune Sciences Address


Market Capitalization: 380 171 000 $

Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.

EBITDA: -52 564 000 $

EBITDA is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth


Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.


Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -1.748

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.017
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 1.385

Enterprise Value (EV) /Revenue

EV To EBITDA: -0.857

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 45914400

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Alpine Immune Sciences price target for 2022 by month

Alpine Immune Sciences (ALPN) stock dividend

Alpine Immune Sciences last paid dividends on 01/01/1970. The next scheduled payment will be on 07/25/2017. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

Related stocks from Healthcare sector


All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.